Google DeepMind is ready to start human trials of AI-designed drugs; company exec says, ‘We’re getting very close’

Google DeepMind’s drug discovery arm, Isomorphic Labs, is “ready” to begin human trials of its AI-designed drugs. In an interview with Fortune, Colin Murdoch, President of Isomorphic Labs and Google DeepMind’s Chief Business Officer, said that the company is “getting very close” to starting human trials of these drugs. This development signifies a potential step for Isomorphic Labs after years of work on its AI-assisted drug designing. Isomorphic Labs was established as a separate entity from DeepMind in 2021. Its foundation stems from AlphaFold, a notable AI system developed by DeepMind, recognised for its ability to predict protein structures with considerable accuracy.

What Google DeepMind exec said about starting human trials for AI-designed drugs